Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 6/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | MET | P08581 | 3/20 | 0.41 |
| ▸ | TTK | P33981 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15073979 | 0.82 | AXL (0.47) | AXLLRRK2PIM1METTTK | |
| SCHEMBL29882342 | 0.82 | AXL (0.47) | AXLLRRK2PIM1METTTK | |
| SCHEMBL16914113 | 0.80 | AXL (0.45) | AXLLRRK2PIM1METTTK | |
| SCHEMBL19576888 | 0.78 | AXL (0.44) | AXLLRRK2PIM1METTTK | |
| SCHEMBL1814407 | 0.73 | LRRK2 (0.51) | AXLLRRK2METTTKAURKA | |
| SCHEMBL15074158 | 0.73 | AXL (0.42) | AXLLRRK2PIM1TTKAURKA | |
| SCHEMBL20929129 | 0.73 | AXL (0.40) | AXLLRRK2PIM1METTTK | |
| SCHEMBL17816457 | 0.72 | PIM1 (0.41) | AXLLRRK2PIM1TTKAURKA | |
| SCHEMBL16701213 | 0.72 | AXL (0.41) | AXLLRRK2PIM1TTKKIT | |
| SCHEMBL31276732 | 0.72 | AXL (0.47) | AXLLRRK2PIM1METTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022164789-A9 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | SCHRÖDINGER, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-2794613-B1 | CONDENSED TRICLYCLIC COMPOUNDS AS INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INT (DE) | 2017-03-29 | — | — | EP | disclosed |
| US-9399645-B2 | Inhibitors of HIV replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-07-26 | — | — | US | disclosed |
| US-9399645-B2 | Inhibitors of HIV replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-07-26 | — | — | US | disclosed |
| US-20150011531-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-08 | — | — | US | disclosed |
| US-20150011531-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-08 | — | — | US | disclosed |
| WO-2013091096-A1 | CONDENSED TRICLYCLIC COMPOUNDS AS INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011531-A1 | INHIBITORS OF HIV REPLICATION | MCM3, REV1, POLR2E | AXL 2324/4885LRRK2 1309/4885PIM1 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.